Evidence map›Paper›PMID 36843578›Full record

ReviewFrontiers in endocrinology2023

GLP-1 receptor agonists for the treatment of obesity: Role as a promising approach.

Jing-Yue Wang, Quan-Wei Wang, Xin-Yu Yang, Wei Yang, Dong-Rui Li, Jing-Yu Jin, Hui-Cong Zhang, Xian-Feng Zhang

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in endocrinology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 152 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
152citing papers in PubMed, 9 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

152 citing papers in PubMed, 9 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Guideline
  8. Pooled it
  9. Pooled it
  10. Trial
  11. Trial
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. The βBritish journal of pharmacology · 2026
    Article
  20. Review

92 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jing-Yue WangDepartment of Cardiovascular Medicine, The First Hospital of Jilin University, Changchun, China.
Quan-Wei WangDepartment of Cardiovascular Medicine, The First Hospital of Jilin University, Changchun, China.
Xin-Yu YangDepartment of Cardiovascular Medicine, The First Hospital of Jilin University, Changchun, China.
Wei YangDepartment of Cardiovascular Medicine, The First Hospital of Jilin University, Changchun, China.
Dong-Rui LiDepartment of Cardiovascular Medicine, The First Hospital of Jilin University, Changchun, China.
Jing-Yu JinDepartment of Cardiovascular Medicine, The First Hospital of Jilin University, Changchun, China.
Hui-Cong ZhangDepartment of Cardiovascular Medicine, The First Hospital of Jilin University, Changchun, China.
Xian-Feng ZhangDepartment of Neurosurgery, The First Hospital of Jilin University, Changchun, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Obesity is a complex disease characterized by excessive fat accumulation which is caused by genetic, environmental and other factors. In recent years, there has been an increase in the morbidity, disability rate,and mortality due to obesity, making it great threat to people's health and lives, and increasing public health care expenses. Evidence from previous studies show that weight loss can significantly reduce the risk of obesity-related complications and chronic diseases. Diet control, moderate exercise, behavior modification programs, bariatric surgery and prescription drug treatment are the major interventions used to help people lose weight. Among them, anti-obesity drugs have high compliance rates and cause noticeable short-term effects in reducing obese levels. However, given the safety or effectiveness concerns of anti-obesity drugs, many of the currently used drugs have limited clinical use. Glucagon-like peptide-1 receptor (GLP-1R) agonists are a group of drugs that targets incretin hormone action, and its receptors are widely distributed in nerves, islets, heart, lung, skin, and other organs. Several animal experiments and clinical trials have demonstrated that GLP-1R agonists are more effective in treating or preventing obesity. Therefore, GLP-1R agonists are promising agents for the treatment of obese individuals. This review describes evidence from previous research on the effects of GLP-1R agonists on obesity. We anticipate that this review will generate data that will help biomedical researchers or clinical workers develop obesity treatments based on GLP-1R agonists.

Indexed as

Anti-Obesity AgentsGlucagon-Like Peptide-1 Receptor AgonistsAnimalsIncretinsObesityWeight LossAnti-Obesity AgentsGlucagon-Like Peptide-1 Receptor AgonistsIncretinsdual agonismGLP-1R agonistsmetabolic diseasesobesityweight-reducing drugs

Identifiers

PMID36843578
PMCPMC9945324

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.